Compare AGCO Corporation (AGCO) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AGCO Corporation vs Enveric Biosciences Inc — how do they compare? AGCO Corporation trades at $113.41 (market cap $8.24B), while Enveric Biosciences Inc trades at $1.37 (market cap $5.84M). The key difference: AGCO Corporation is far larger — about 1411× Enveric Biosciences Inc's market cap, and AGCO Corporation pays a 1.05% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| AGCO | ENVB | |
|---|---|---|
Market Cap | $8.24B | $5.84M |
Sector | Industrials | Health |
52-Week High | $140.49 | $17.40 |
52-Week Low | $100.14 | $1.28 |
Enterprise Value | $10.41B | $932.52K |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGCO trades at $113.75, down 2.35% today, with a neutral technical signal and bullish moving averages. The company shows solid fundamentals with a P/E of 11.41 and net income margin of 7.43%, supported by three consecutive earnings beats. Recent news highlights marketing initiatives and fuel efficiency advancements, while cash flow improved to $249.10M in 2025 from negative levels in prior years.
The outlook remains positive with a consensus price target of $147.50, implying 30% upside, though risks include agricultural sector volatility and debt levels. Earnings momentum and valuation discounts present opportunities, but investor sentiment is balanced with equal buy/hold ratings from analysts.
ENVB trades at $1.48, up 2.07% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, with negative ROE and ROA, yet consistently beat earnings expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies.
The outlook is mixed: strong analyst support (75% buy ratings) and positive clinical updates contrast with deep losses and bearish technicals. Key risks include clinical trial outcomes and cash burn, while institutional financing provides near-term stability. Upside depends on successful drug development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AGCO Corporation
Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
